BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21193420)

  • 1. MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context.
    Kleppe M; Mentens N; Tousseyn T; Wlodarska I; Cools J
    Haematologica; 2011 May; 96(5):779-83. PubMed ID: 21193420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
    Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
    Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
    De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
    Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
    Kleppe M; Soulier J; Asnafi V; Mentens N; Hornakova T; Knoops L; Constantinescu S; Sigaux F; Meijerink JP; Vandenberghe P; Tartaglia M; Foa R; Macintyre E; Haferlach T; Cools J
    Blood; 2011 Jun; 117(26):7090-8. PubMed ID: 21551237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
    Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
    Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines.
    Porcu M; Gielen O; Cools J; De Keersmaecker K
    Haematologica; 2009 Mar; 94(3):435-7. PubMed ID: 19176360
    [No Abstract]   [Full Text] [Related]  

  • 8. Distinct sensitivity of CD8+ CD4- and CD8+ CD4+ leukemic cell subpopulations to cyclophosphamide and rapamycin in Notch1-induced T-ALL mouse model.
    Zhang Y; Hua C; Cheng H; Wang W; Hao S; Xu J; Wang X; Gao Y; Zhu X; Cheng T; Yuan W
    Leuk Res; 2013 Nov; 37(11):1592-601. PubMed ID: 24090996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.
    Marchesini M; Gherli A; Montanaro A; Patrizi L; Sorrentino C; Pagliaro L; Rompietti C; Kitara S; Heit S; Olesen CE; Møller JV; Savi M; Bocchi L; Vilella R; Rizzi F; Baglione M; Rastelli G; Loiacono C; La Starza R; Mecucci C; Stegmaier K; Aversa F; Stilli D; Lund Winther AM; Sportoletti P; Bublitz M; Dalby-Brown W; Roti G
    Cell Chem Biol; 2020 Jun; 27(6):678-697.e13. PubMed ID: 32386594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
    Aste-Amézaga M; Zhang N; Lineberger JE; Arnold BA; Toner TJ; Gu M; Huang L; Vitelli S; Vo KT; Haytko P; Zhao JZ; Baleydier F; L'Heureux S; Wang H; Gordon WR; Thoryk E; Andrawes MB; Tiyanont K; Stegmaier K; Roti G; Ross KN; Franlin LL; Wang H; Wang F; Chastain M; Bett AJ; Audoly LP; Aster JC; Blacklow SC; Huber HE
    PLoS One; 2010 Feb; 5(2):e9094. PubMed ID: 20161710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL.
    Barata JT; Boussiotis VA; Yunes JA; Ferrando AA; Moreau LA; Veiga JP; Sallan SE; Look AT; Nadler LM; Cardoso AA
    Blood; 2004 Mar; 103(5):1891-900. PubMed ID: 14615384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
    Zenatti PP; Ribeiro D; Li W; Zuurbier L; Silva MC; Paganin M; Tritapoe J; Hixon JA; Silveira AB; Cardoso BA; Sarmento LM; Correia N; Toribio ML; Kobarg J; Horstmann M; Pieters R; Brandalise SR; Ferrando AA; Meijerink JP; Durum SK; Yunes JA; Barata JT
    Nat Genet; 2011 Sep; 43(10):932-9. PubMed ID: 21892159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis.
    Oki T; Kitaura J; Watanabe-Okochi N; Nishimura K; Maehara A; Uchida T; Komeno Y; Nakahara F; Harada Y; Sonoki T; Harada H; Kitamura T
    Leukemia; 2012 May; 26(5):1038-45. PubMed ID: 22116551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1.
    Li X; Gounari F; Protopopov A; Khazaie K; von Boehmer H
    J Exp Med; 2008 Nov; 205(12):2851-61. PubMed ID: 18981238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
    Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
    Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
    Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
    Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
    Medyouf H; Gao X; Armstrong F; Gusscott S; Liu Q; Gedman AL; Matherly LH; Schultz KR; Pflumio F; You MJ; Weng AP
    Blood; 2010 Feb; 115(6):1175-84. PubMed ID: 20008304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
    Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
    J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.
    De Keersmaecker K; Versele M; Cools J; Superti-Furga G; Hantschel O
    Leukemia; 2008 Dec; 22(12):2208-16. PubMed ID: 18784740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell receptor-driven lymphomagenesis in mice derived from a reprogrammed T cell.
    Serwold T; Hochedlinger K; Swindle J; Hedgpeth J; Jaenisch R; Weissman IL
    Proc Natl Acad Sci U S A; 2010 Nov; 107(44):18939-43. PubMed ID: 20956329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.